DecisionView (San Francisco, CA) announced today that its Web-based enrollment application, StudyOptimizer, will now be available as Software-as-a-Service (SAS). In addition to faster deployment, the pay-as-you-go version will deliver a lower cost of ownership, says the company.
"We realized the importance of accelerating the adoption of our solution, so that customers could implement corrective actions in their enrollment processes as quickly as possible," said Jim Scullion, Chief Executive Officer of DecisionView. "With the launch of this new offering, companies can leverage the planning and forecasting capabilities of StudyOptimizer in a shorter time frame, even on a single trial."
The SAS model will be hosted in a SAS70 certified infrastructure and is available now.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.